Cathay Capital leads €30m round for Biose

The company's management team, some banking partners and the Auvergne-Rhône-Alpes region also took part in the investment.

Biose intends to use the fresh capital to accelerate the development of its product and strengthen its position in the field of microbiome therapeutics. With Cathay's support, the company plans to expand in the US and Chinese markets.

Company
Founded in 1951 and based in Aurillac, Biose specialises in the development and production of drugs from living bacteria for pharmaceutical laboratories and biotech companies worldwide.

The company develops its products from primarily human microbiota, which consists of billions of beneficial microorganisms populating the organs of a healthy individual. Drug candidates using some of these microorganisms are being developed to cure diseases including Crohn's disease, autism, certain cancers and Covid-19.

People
Biose Industrie – Adrien Nivoliez (CEO).
Cathay Capital – Fabien Wesse (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Technology
• Cathay Capital
• Venture
• France